ECEESPE2025 ePoster Presentations Fetal and Neonatal Endocrinology (27 abstracts)
Serum neudesin levels in patients with congenital hypothyroidism
Semra Bahar Akın 1 , Ilker Tolga Özgen 2 , Yasar Cesur 3 , Caner Yıldız 4 , Ömer Faruk Özer 5 , Emel Hatun Aytaç Kaplan 6 & Zümrüt Kocabey Sütçü 6
1Derince Training And Research Hospital, Department Of Pedıatrıc Endocrınology, Kocaeli, Türkiye; 2Bırunı Unıversıty Faculty Of Medıcıne, Department Of Pedıatrıc Endocrınology, Istanbul, Türkiye; 3Bezmıalem Unıversıty Faculty Of Medıcıne, Department Of Pedıatrıc Endocrınology, Istanbul, Türkiye; 4Bezmıalem Unıversıty Faculty Of Medıcıne, Department Of Biochemistry, Istanbul, Türkiye; 5Bezmıalem Unıversıty Faculty Of Medıcıne, Department Of Biochemistry, Department Of Biochemistry, Istanbul, Türkiye; 6Cam ve Sakura City Hospital, Department of Pediatric Endocrinology, Istanbul, Türkiye
JOINT2817
Objectives: Neudesin is a newly discovered protein mainly secreted from adipose tissue and the brain. It plays a role as a neurotrophic factor in the brain and a negative regulator of energy expenditure. Neurodevelopmental delay and cognitive dysfunction are common features in cases with congenital hypothyroidism (CH) without treatment. Considering neudesin’s role in brain development and its contribution to the survival of mature neurons, any possible relationships between neudesin and thyroid hormone were evaluated.
Methods: A total of 52 patients (32 patients with CH, 14 females and 18 males, aged 19± 7 days; 20 healthy subjects for the control group; 7 females and 13 males, aged 22± 8 days) were included in the study. All patients were evaluated for thyroid hormones and plasma neudesin levels. The basal neudesin levels between the patient and control groups and the patients’ neudesin levels before and after l-thyroxine treatment were compared.
Results: Regarding basal neudesin levels, there was no statistically significant difference (6.77±6.41 vs 7.93±7.04 ng/mL) (P = 0.552) between the CH and control groups respectively. However, neudesin levels increased following one month of therapy (6.46±6.63 vs 12.85±18.74 ng/mL) in the CH group; this difference was statistically significant (P = 0.019).
Conclusion: Although there was no difference in basal neudesin levels between the patient and control groups, neudesin levels increased with treatment. However, more extensive and different studies are needed to understand the pathophysiological role of this relationship in the disease or the recovery process.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more